Sujata Ojha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sujata Ojha has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Boone Goodgame
Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Health Discovery Building, 1601 Trinity St, Room 7700B, Austin, TX 78712, USA
1 shared publication - Kyaw Lwin Aung
Department of Gastrointestinal Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL
1 shared publication Madeline Fitzpatrick
Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Health Discovery Building, 1601 Trinity St, Room 7700B, Austin, TX 78712, USA
1 shared publication- Matthew R Barke
Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Health Discovery Building, 1601 Trinity St, Room 7700B, Austin, TX 78712, USA
1 shared publication - William Sessions
Division of Hematology and Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA
1 shared publication - Yuhang Zhou
Division of Hematology and Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by MDPI AG in Preprints.org
Circulating Tumor DNA in Pancreatic Adenocarcinoma: A Critical Appraisal: ctDNA in Pancreatic Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, due to late diagnosis, and limited treatment options. Circulating tumor DNA (ctDNA), is a promising, minimally invasive biomarker that could improve the clinical outcomes of patients with PDAC by enabling early disease detection, minimal residual disease (MRD) assessment, precise prognostication, and accurate treatment monitoring. CtDNA has prognostic as well as predictive value in both resectable and metastatic settings, with serial measurements enhancing risk stratification and recurrence prediction beyond CA19-9. However, despite the promise, the true potential of ctDNA has not yet been fulfilled in patients with PDAC. The current limitations include a low sensitivity of ctDNA assays in early-stage PDAC, challenges in the assay interpretation due to specific nature of ctDNA shedding in PDAC, inter-patient heterogeneity, and technical variability. As precision oncology advances, ctDNA will be a powerful tool for personalized care in PDAC but rigorous validation of its use within specific clinical contexts is still needed before the true potential of ctDNA is realized for the patients with PDAC.
- 27 August 2025
- Published by MDPI AG in Preprints.org
Open AccessCirculating Tumor DNA in Pancreatic Adenocarcinoma: A Critical Appraisal: ctDNA in Pancreatic Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, due to late diagnosis, and limited treatment options. Circulating tumor DNA (ctDNA), is a promising, minimally invasive biomarker that could improve the clinical outcomes of patients with PDAC by enabling early disease detection, minimal residual disease (MRD) assessment, precise prognostication, and accurate treatment monitoring. CtDNA has prognostic as well as predictive value in both resectable and metastatic settings, with serial measurements enhancing risk stratification and recurrence prediction beyond CA19-9. However, despite the promise, the true potential of ctDNA has not yet been fulfilled in patients with PDAC. The current limitations include a low sensitivity of ctDNA assays in early-stage PDAC, challenges in the assay interpretation due to specific nature of ctDNA shedding in PDAC, inter-patient heterogeneity, and technical variability. As precision oncology advances, ctDNA will be a powerful tool for personalized care in PDAC but rigorous validation of its use within specific clinical contexts is still needed before the true potential of ctDNA is realized for the patients with PDAC.
- Open Access
- 11 May 2025
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Oncology
- Vol. 11 (1) , 9-13
Empyema after radiation therapy for cutaneous squamous cell carcinoma in a patient with scleroderma
Introduction: Cutaneous squamous cell carcinoma (cSCC) is a non-melanomatous neoplasm of the skin that is more likely to develop in immunosuppressed patients or those with autoimmune diseases. Individuals with connective tissue disorders in particular, such as scleroderma, are particularly at an increased risk of developing cancer due to chronic inflammation, tissue damage, genetic susceptibility, and immunosuppressive therapy. Additionally, treatment of cSCC with surgery and radiation therapy, especially in those with autoimmune connective tissue disorders, presents an increased risk of adverse effects, including infection. Case Report: A 74-year-old woman with a history of systemic scleroderma and cSCC status post Mohs surgical resection and radiation therapy presented with an 8-cm forehead lesion at the site of excised cSCC. One year earlier, she underwent Mohs surgery after biopsy-proven cSCC of the forehead with resulting clear margins. Radiation therapy was recommended as nerve involvement was discovered within the resected tumor. Magnetic resonance imaging of the brain revealed a right parafalcine subdural empyema with peripheral blood and intraoperative cultures positive for Streptococcus intermedius and Candida albicans. Her hospitalization was complicated by the development of acute hypoxic respiratory failure and septic shock. Ultimately, her family chose to focus on her comfort and she passed peacefully from complications of septic shock. Conclusion: This case highlights a rare infection after treatment of cSCC which emphasizes that treatment of malignant skin lesions in patients with scleroderma can be challenging. Shared decision-making with a thorough assessment of risks should be emphasized with every patient before proceeding with treatment.
- 11 May 2025
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Oncology
- Vol. 11 (1) , 9-13
Open AccessEmpyema after radiation therapy for cutaneous squamous cell carcinoma in a patient with scleroderma
Introduction: Cutaneous squamous cell carcinoma (cSCC) is a non-melanomatous neoplasm of the skin that is more likely to develop in immunosuppressed patients or those with autoimmune diseases. Individuals with connective tissue disorders in particular, such as scleroderma, are particularly at an increased risk of developing cancer due to chronic inflammation, tissue damage, genetic susceptibility, and immunosuppressive therapy. Additionally, treatment of cSCC with surgery and radiation therapy, especially in those with autoimmune connective tissue disorders, presents an increased risk of adverse effects, including infection. Case Report: A 74-year-old woman with a history of systemic scleroderma and cSCC status post Mohs surgical resection and radiation therapy presented with an 8-cm forehead lesion at the site of excised cSCC. One year earlier, she underwent Mohs surgery after biopsy-proven cSCC of the forehead with resulting clear margins. Radiation therapy was recommended as nerve involvement was discovered within the resected tumor. Magnetic resonance imaging of the brain revealed a right parafalcine subdural empyema with peripheral blood and intraoperative cultures positive for Streptococcus intermedius and Candida albicans. Her hospitalization was complicated by the development of acute hypoxic respiratory failure and septic shock. Ultimately, her family chose to focus on her comfort and she passed peacefully from complications of septic shock. Conclusion: This case highlights a rare infection after treatment of cSCC which emphasizes that treatment of malignant skin lesions in patients with scleroderma can be challenging. Shared decision-making with a thorough assessment of risks should be emphasized with every patient before proceeding with treatment.